The natural history of chronic HBV infection and geographical differences

Antiviral Therapy

Volumn 15, Issue SUPPL. 3, 2010, Pages 25-33

  Liaw, Yun Fan ^a   Brunetto, Maurizia R ^b   Hadziyannis, Stephanos ^c  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c HENRY DUNANT HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ASIA; CANCER RISK; CENTRAL AFRICA; CENTRAL AMERICA; CIGARETTE SMOKING; COMPARATIVE STUDY; DISEASE EXACERBATION; FRANCE; GENE MUTATION; GENOTYPE; GEOGRAPHIC DISTRIBUTION; GEOGRAPHY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE MEDIATED INJURY; IMMUNE RESPONSE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER INJURY; MEXICO; NONHUMAN; ONSET AGE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SEROCONVERSION; SEX RATIO; SOUTH AFRICA; SOUTH AMERICA; UNITED STATES; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS TRANSMISSION; VIRUS TYPING; WESTERN HEMISPHERE;

GENOTYPE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; WORLD HEALTH;

EID: 77957332676     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1621     Document Type: Review

References (81)

1. US Centers for Disease Control and Prevention. CDC Travel's Health - 2010 Yellow Book. Chapter 2 - Hepatitis B. (Updated 6 October 2009. Accessed 18 June 2010.) Available from http:/wwwnc.cdc.gov/travel/yellowbook/2010/chapter-2/ hepatitis-b.aspx
2. Miyakawa Y, Mizokami M. Classifying hepatitis B virus genotypes. Intervirology 2003; 46:329-338.
3. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11:97-107.
4. Chu CM, Liaw YF. Natural history differences in perinatally versus adult-acquired disease. Current Hepatitis Reports 2004; 3:123-131.
5. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373:582-592.
6. Hadziyannis SJ. Nonparenteral transmission of viral hepatitis in Greece. Am J Med Sci 1975; 270:313-318.
7. Blumberg BS, Hesser JE, Economidou I, et al. The variety of responses within a community to infection with Australia (hepatitis B) antigen. Dev Biol Stand 1975; 30:270-283.
8. Hadziyannis SJ, Dourakis SP, Papaioannou C, Alexopoulou A, Hadziyannis ES, Gioustozi A. Changing epidemiology and spreading modalities of hepatitis delta virus infection in Greece. Prog Clin Biol Res 1993; 382:259-266.
9. McMahon BJ. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol Int 2009; 3:334-342.
10. Hui CK, Leung N, Yuen ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 2007; 46:395-401. (Pubitemid 47344774)
11. Sheen IS, Liaw YF, Tai DI, Chu CM. Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis. Gastroenterology 1985; 89:732-735.
12. Liaw YF. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol 2003; 18:246-252.
13. Yuen MF, Sablon E, Hui CK, et al. Prognostic factors in severe exacerbation of chronic hepatitis B. Clin Infect Dis 2003; 36:979-984. (Pubitemid 36513281)
14. Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004; 116:829-834.
15. Chu CM, Yeh CT, Lee CS, Sheen IS, Liaw YF. Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion. J Clin Microbiol 2002; 40:16-21.
16. Yuen MF, Sablon E, Yuan HJ, et al. Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus. J Infect Dis 2002; 186:1335-1338.
17. Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis 2006; 26:130-141.
18. Chu CM, Liaw YF. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepat 2007; 14:147-152.
19. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002; 122:1756-1762.
20. Ni YH, Chang MH, Wang KJ, et al. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology 2004; 127:1733-1738.
21. Yuen MF, Sablon E, Tanaka Y, et al. Epidemiological study of hepatitis B virus genotypes, core promoter and precore mutations of chronic hepatitis B infection in Hong Kong. J Hepatol 2004; 41:119-125. (Pubitemid 39005162)
22. Chu CM, Liaw YF. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol 2005; 43:411-417.
23. Livingston SE, Simonetti JP, Bulkow LR, et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology 2007; 133:1452-1457.
24. Ni YH, Chang MH, Chen PJ, et al. Viremia profiles in children with chronic hepatitis B virus infection and spontaneous e antigen seroconversion. Gastroenterology 2007; 132:2340-2345.
25. Fattovich G, Olivari N, Pasino M, D'Onofrio M, Martone E, Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008; 57:84-90.
26. Hadziyannis SJ. Hepatitis B e antigen-negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepatitis Reviews 1995; 1:7-36.
27. Hadziyannis S, Gerber MA, Vissoulis C, Popper H. Cytoplasmic hepatitis B antigen in 'ground-glass' hepatocytes of carriers. Arch Pathol 1973; 96:327-330.
28. Schalm SW, Thomas HC, Hadziyannis SJ. Chronic hepatitis B. Prog Liver Dis 1990; 9:443-462.
29. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34:617-624.
30. Hadziyannis S, Bramou T, Alexopoulou A, Makris A. Immunopathogenesis and natural course of anti-HBe-positive chronic hepatitis with replicating B virus. In Hollinger FB, Lemon SM, Margolis HS (Editors). Viral Hepatitis and Liver Disease. Baltimore: Lippincott Williams & Wilkins 1991; pp. 673-676.
31. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35:1522-1527.
32. Manno M, Cammà C, Schepis F, et al. Natural history of chronic HBV carriers in Northern Italy: morbidity and mortality after 30 years. Gastroenterology 2004; 127:756-763.
33. Zacharakis GH, Koskinas J, Kotsiou S, et al. Natural history of chronic HBV infection: a cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project). J Med Virol 2005; 77:173-179.
34. Bortolotti F, Guido M, Bartolacci S, et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology 2006; 43:556-562.
35. Tai DI, Lin SM, Sheen IS, Chu CM, Lin DT, Liaw YF. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology 2009; 49:1859-1867.
36. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007; 45:1187-1192.
37. Sánchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodés J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002; 123:1848-1856.
38. Yuen MF, Wong DK, Sablon E, et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 2004; 39:1694-1701.
39. Hadziyannis S, Sevastianos V, Georgiou A, Hadziyannis S. Treatment related compared to spontaneous occurring HBsAg loss in HBeAg negative chronic hepatitis B. Hepatology 2009; 50 Suppl 4:509A.
40. Yeh CT, Chang MH, Lai HY, Chang ML, Chu CM, Liaw YF. Identification of a novel pre-S2 mutation in a subgroup of chronic carriers with spontaneous clearance of hepatitis B virus surface antigen. J Gastroenterol Hepatol 2003; 18:1129-1138.
41. Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous HBeAg seroconversion in chronic hepatitis B. Hepatology 2010; 51:435-444.
42. Lok AS, Hadziyannis SJ, Weller IV, et al. Contribution of low level HBV replication to continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B virus infection. Gut 1984; 25:1283-1287.
43. Bonino F, Brunetto MR. Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview. J Hepatol 2003; 39 Suppl 1:S160-S163.
44. Chu CM, Liaw YF. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Am J Gastroenterol 2009; 104:1693-1699.
45. Chu CM, Liaw YF. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology 2007; 133:1458-1465.
46. Feld JJ, Ayers M, El-Ashry D, Mazzulli T, Tellier R, Heathcote EJ. Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2007; 46:1057-1070.
47. Chu CJ, Keeffe EB, Han SH, et al. Prevalence of HBV precore/core promoter variants in the United States. Hepatology 2003; 38:619-628.
48. Dimou E, Rapti I, Kostamena A, Laras A, Hadziyannis S. Development of precore and basic core promoter HBV mutations in chronic hepatitis B genotypes D and A. A prospective study in a Caucasian population. Hepatology 2009; 50 Suppl 4:983A.
49. Manesis EK. HBeAg-negative chronic hepatitis B: from obscurity to prominence. J Hepatol 2006; 45:343-346.
50. Papatheodoridis GV, Chrysanthos N, Hadziyannis E, Cholongitas E, Manesis EK. Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. J Viral Hepat 2008; 15:434-441.
51. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. The Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) study group predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-686.
52. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73.
53. Iloeje UH, Yang HI, Jen CL, et al. Risk evaluation of viral load elevation and associated liver disease/cancer-hepatitis B virus study group. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol 2007; 5:921-931.
54. Liaw YF. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther 2006; 11:669-679.
55. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8:493-496.
56. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347:168-174.
57. Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46:45-52.
58. Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36:263-270.
59. Park BK, Park YN, Ahn SH, et al. Long-term outcome of chronic hepatitis B based on histological grade and stage. J Gastroenterol Hepatol 2007; 22:383-388.
60. Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 2006; 26:142-152.
61. Chen YC, Chu CM, Yeh CT, Liaw YF. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int 2007; 1:267-273.
62. Fattovich G, Pantalena M, Zagni I, et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002; 97:2886-2895.
63. Yu MW, Chang HC, Liaw YF, et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 2000; 92:1159-1164.
64. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48:335-352.
65. Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005; 97:265-272.
66. Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:1134-1143.
67. Chen CH, Hung CH, Lee CM, et al. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology 2007; 133:1466-1474.
68. Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 2009; 29 Suppl 1:100-107.
69. Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12:S294-S308.
70. Tong MJ, Blatt LM, Tyson KB, Kao VWC. Death from liver disease and development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection: a prospective study. Gastroenterol Hepatol 2006; 2:41-47.
71. Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42:121-129.
72. Villeneuve JP, Desrochers M, Infante-Rivard C, et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994; 106:1000-1005.
73. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61:1942-1956.
74. Sakuma K, Saitoh N, Kasai M, et al. Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: a prospective study. Hepatology 1988; 8:1642-1646.
75. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med 1990; 150:1051-1054.
76. Tsai SL, Yang PM, Lai MY, et al. Natural-history of hepatitis-B surface antigen-positive cirrhosis in Taiwan: a clinicopathological study. J Gastroenterol Hepatol 1988; 3:583-592.
77. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28:930-938.
78. Liaw YF, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-1531.
79. Sugiyama M, Tanaka Y, Kato T, et al. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology 2006; 44:915-924.
80. Manigold T, Rehermann B. Chronic hepatitis B and hepatocarcinogenesis: does prevention of 'collateral damage' bring the cure? Hepatology 2003; 37:707-710.
81. Kew MC, Kramvis A, Yu MC, Arakawa K, Hodkinson J. Increased hepatocarcinogenic potential of hepatitis B virus genotype A in Bantu-speaking sub-Saharan Africans. J Med Virol 2005; 75:513-521.